Entrepreneurs Evening at The Bradfield Centre


Are you an experienced or aspiring entrepreneur? Have you wondered what it takes to create an investment idea with potential, or how to spot one? Are you an investor who would like to find out more about the angel investment and venture capital scene in Cambridge?

Cambridge is one of the biggest and most successful markets in Europe for entrepreneurs and venture capital investors. The Trinity Business and City Association is hosting an evening at the Bradfield Centre, on Tuesday, 19 November 2019, exploring the entrepreneurial and investment activity in and around Cambridge.

Confirmed Speakers

Ian Tomlinson (1987)
Chair of Apollo Therapeutics

Tom Macura (2004)
Chief Operating Officer at WiseAlpha

Graham Schwikkard
Chief Executive Officer at SyndicateRoom

The evening will provide an opportunity for experienced entrepreneurs, venture capitalists and investors to share their experience of successfully funding great ideas and businesses.

Our expert speakers will give an insight into their journeys and reveal their strategies for success, and things to avoid, during the panel discussion. This will be followed by networking drinks and canapés.

The event is organised in collaboration with The Bradfield Centre, Cambridge’s hub for tech and deep tech companies, operated by Central Working. Our mission is to grow scaleups and provide them with the connections and support they need to thrive. The way we do this is by building a sense of community through human interactions and high-quality events which engage our members and allow for networking.


Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. After graduating from Trinity College, Cambridge he spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry. He then co-founded Domantis Limited with Nobel Laureate Sir Gregory Winter, which was focused on the development of an entirely new class of drugs based on the smallest fragments of antibodies, known as domain antibodies and was acquired by GSK for $454 million. At GSK he served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D. An active member of the GSK R&D Leadership Team, Ian was also a member of several of GSK’s main governance committees, including Chairing the Technology Investment Board (TIB) and the Platforms and Capabilities Investment Board (PCIB), the latter being responsible for co-ordinating direct and indirect investment for all GSK’s R & D pre-clinical and clinical platforms, with an annual spend of approximately £1.5 billion. Following his departure from GSK in 2016, Ian is now Chair of the Stevenage Bioscience Catalyst, UK’s first open innovation biomedical campus, Chair of Apollo Therapeutics, a £40 million partnership with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge dedicated to turning academic discoveries into novel therapies in collaboration and Chair of Start Codon, a Cambridge based accelerator supporting and mentoring early stage lifescience companies.

Tom is managing day to day operations at WiseAlpha which created a world-first bond fraction trading platform that is revolutionising the multi-trillion corporate bond market. WiseAlpha’s mission is to help create a fairer investment world where everyday investors are not shut-out by the financial elite from accessing the best investments. Tom joined WiseAlpha after a 10 year career at Goldman Sachs. He matriculated at Trinity in 2004 as a post-graduate student and graduated in 2008 with a PhD in Computer Science.

Graham joined SyndicateRoom as COO in 2017 and helped develop and grow SR’s fund offering. He took over as CEO in June 2019 to implement a new strategic vision focused on data-driven funds and democratising startup investing. Under Graham’s stewardship, SR has doubled its portfolio to almost 200 companies and helped raise over £150m for high growth technology companies. Graham came to the UK from South Africa to study at the University of Cambridge’s business school (the Cambridge Judge Business School), where he completed his MBA, with distinction. In addition, Graham holds a degree in Genetics. Prior to joining SyndicateRoom, Graham worked as a management consultant.


6:30 pm


7:00 pm

Panel Discussion

8:00 pm

Networking Drinks

9:00 pm



184 Cambridge Science Park
Milton Road, Milton
Cambridge, CB4 0GA


Cambridge is served by two train stations. Cambridge (station code CBG), which is 20-25 minutes by car, and the closer Cambridge North (station code CMB) which is 5 minutes by car, 10 mins by bike, or a 20 minute walk. Eight Bike & Go Bikes are available at Cambridge North Station.